| Cat.No. | Name | Information |
|---|---|---|
| M1764 | PF-477736 | PF-477736 is a selective checkpoint kinase 1 (Chk1) inhibitor with Ki values of 0.49 nM and 47 nM for CHK1 and CHK2 respectively. |
| M1665 | AZD7762 | AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively. |
| M2325 | CHIR-124 | CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM. |
| M5137 | BML-277 | BML-277 is a high efficient Chk2 inhibitors, IC50 is 15 nM. |
| M41445 | CHK1-IN-7 | CHK1-IN-7 is a potent human CHK1 inhibitor. |
| M30540 | Chk2-IN-1 | Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect. |
| M29247 | MU380 | MU380 is a potent and selective CHK1 inhibitor that induces apoptosis and has anticancer activity. |
| M27925 | GDC-0425 | GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies. |
| M27924 | GNE-900 | GNE-900 is a an ATP-competitive, selective, and orally active ChK1 inhibitor with IC50s of 0.0011, 1.5 µM for ChKl, ChK2, respectively. GNE-900 abrogates the G2-M checkpoint, enhances DNA damage, and induces Apoptosis. gemcitabine and GNE-900 administration shows anti-tumor activity. |
| M27916 | GDC0575 hydrochloride | GDC0575 (ARRY-575) hydrochloride is a highly-selective and orally active Chk1 (IC50=1.2 nM) inhibitor. GDC0575 (ARRY-575) hydrochloride can be used for colitis-associated cancer (CAC) and colitis research. |
| M27884 | VER-00158411 | VER-00158411 is a checkpoint kinase 1 (CHK1) and CHK2 inhibitor with IC50 values of 4.4 nM and 4.5 nM, respectively. |
| M21501 | Monalizumab | Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer cell population 2A (NKG2A). Monalizumab can be used in the study of head and neck squamous cell carcinoma (HNSCC). |
| M20032 | WAY-239320 | WAY-239320 is a Chk1 inhibitor |
| M13623 | Prexasertib dimesylate | Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. |
| M13620 | CCT244747 | CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC50 of 7.7 nM; CCT244747 also abrogates G2 checkpoint with an IC50 of 29 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
